Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -28.10 | — | — | — | 15.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 63.81 | — | — | — | 4.33 | 44.48 | 7.01 | 20.39 | 18.00 | 11.69 | 33.18 | 43.66 | 25.45 | 5.02 | 15.10 | 24.87 | 11.49 | 17.24 | 28.85 | 41.90 | 33.42 |
| — | — | — | — | -75.9% | +280.5% | -78.9% | -53.3% | -29.3% | +132.7% | +119.7% | +75.5% | +121.4% | -70.9% | -47.7% | -40.6% | -65.6% | +25.7% | -24.2% | +53.1% | — | |
| P/B Ratio | 8.20 | 4.57 | 7.67 | 2.97 | 5.82 | 4.19 | 0.91 | 1.68 | 3.65 | 3.75 | 3.25 | 3.75 | 3.95 | 1.38 | 1.53 | 2.56 | 1.17 | 1.33 | 2.07 | 2.78 | 2.48 |
| — | +9.0% | +746.6% | +76.6% | +59.8% | +11.8% | -72.1% | -55.1% | -7.7% | +172.4% | +111.9% | +46.6% | +239.0% | +3.4% | -26.1% | -8.0% | -53.1% | -92.7% | -87.7% | -89.3% | -55.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | 15.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 14.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.3% | — | — | — | 100.0% | 80.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 94.3% | 89.7% | 74.7% | 77.4% | 82.4% | 88.1% | 88.4% | 89.9% | -223.0% |
| — | — | — | — | 0.0% | -19.6% | 0.0% | 0.0% | +6.1% | +11.5% | +33.8% | +29.3% | +14.5% | +1.8% | -15.4% | -14.0% | +136.9% | -9.6% | -5.0% | -5.7% | -203.6% | |
| Operating Margin | -178.4% | — | — | — | 26.2% | -1287.9% | -788.8% | -993.7% | -283.3% | -148.7% | -653.0% | -644.7% | -238.8% | -159.2% | -525.3% | -476.8% | -432.4% | -436.7% | -440.8% | -384.6% | -288.3% |
| — | — | — | — | +109.2% | -766.1% | -20.8% | -54.1% | -18.6% | +6.6% | -24.3% | -35.2% | +44.8% | +63.5% | -19.2% | -24.0% | -50.0% | -1640.0% | -133.0% | -293.3% | -221.4% | |
| Net Margin | -162.9% | — | — | — | 29.5% | -1221.4% | -739.5% | -915.0% | -251.3% | -128.6% | -585.9% | -566.4% | -207.4% | -141.9% | -485.7% | -453.3% | -419.8% | -430.7% | -437.8% | -385.7% | -288.6% |
| — | — | — | — | +111.7% | -850.1% | -26.2% | -61.5% | -21.1% | +9.4% | -20.6% | -25.0% | +50.6% | +67.1% | -11.0% | -17.5% | -45.4% | -1640.3% | -130.9% | -297.7% | -221.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -37.2% | -7.8% | -12.3% | -15.3% | 10.8% | -25.8% | -21.8% | -17.6% | -12.2% | -10.0% | -14.7% | -11.6% | -9.1% | -9.4% | -11.7% | -11.1% | -10.2% | -8.0% | -7.6% | -6.2% | -9.3% |
| — | +69.7% | +43.3% | +12.9% | +188.0% | -158.1% | -48.6% | -51.3% | -34.5% | -6.0% | -24.7% | -4.4% | +10.5% | -17.2% | -55.0% | -79.1% | -9.0% | -0.8% | +69.8% | +29.6% | +71.7% | |
| ROA | -28.4% | -7.3% | -10.9% | -12.7% | 7.1% | -15.2% | -13.5% | -11.3% | -7.9% | -6.5% | -9.4% | -7.4% | -5.5% | -5.3% | -6.7% | -6.5% | -6.4% | -5.4% | -5.2% | -4.3% | -5.2% |
| — | +51.7% | +19.2% | -13.0% | +189.2% | -133.8% | -44.0% | -52.1% | -44.2% | -22.7% | -40.6% | -14.8% | +13.4% | +2.1% | -28.5% | -50.8% | -21.4% | -165.4% | +7.6% | +9.3% | +83.5% | |
| ROIC | -38.5% | -9.2% | -13.7% | -15.5% | 7.9% | -22.3% | -20.5% | -16.1% | -11.0% | -9.3% | -13.6% | -10.9% | -8.7% | -8.8% | -10.3% | -10.3% | -11.0% | -9.1% | -9.0% | -8.9% | -16.4% |
| — | +58.8% | +33.0% | +3.7% | +171.7% | -138.8% | -50.8% | -48.5% | -27.4% | -6.5% | -32.0% | -5.3% | +21.3% | +3.6% | -14.7% | -16.2% | +32.9% | +85.3% | +91.2% | -18.6% | +34.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.03 | 0.08 | 0.10 | 0.22 | 0.26 | 0.22 | 0.18 | 0.16 | 0.15 | 0.14 | 0.15 | 0.14 | 0.19 | 0.18 | 0.16 | 0.15 | 0.00 | 0.00 | 0.00 | 0.02 |
| — | -88.0% | -62.2% | -47.0% | +32.3% | +69.8% | +53.2% | +18.9% | +15.0% | -18.4% | -20.6% | -6.7% | -4.2% | +8794.6% | +5324.6% | +3681.4% | +658.9% | -98.4% | -97.4% | -97.9% | — | |
| Debt / EBITDA | — | — | — | — | 2.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 16.32 | 50.82 | 27.38 | 16.32 | 8.88 | 4.75 | 6.26 | 6.98 | 8.00 | 7.49 | 8.23 | 7.54 | 8.54 | 5.98 | 6.39 | 6.76 | 7.83 | 9.76 | 11.75 | 12.10 | 12.30 |
| — | +970.1% | +337.2% | +133.9% | +10.9% | -36.6% | -23.9% | -7.5% | -6.3% | +25.3% | +28.7% | +11.7% | +9.2% | -38.8% | -45.6% | -44.2% | -36.4% | +79.8% | +105.8% | +155.7% | -12.8% | |
| Quick Ratio | 16.32 | 50.82 | 27.38 | 16.32 | 8.88 | 4.75 | 6.26 | 6.98 | 8.00 | 7.49 | 8.23 | 7.54 | 8.54 | 5.98 | 6.39 | 6.76 | 7.83 | 9.76 | 11.75 | 12.10 | 12.30 |
| — | +970.1% | +337.2% | +133.9% | +10.9% | -36.6% | -23.9% | -7.5% | -6.3% | +25.3% | +28.7% | +11.7% | +9.2% | -38.8% | -45.6% | -44.2% | -36.4% | +79.8% | +105.8% | +155.7% | -12.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TNGX stock.
Tango Therapeutics, Inc.'s current P/E is -28.1x. The average P/E over the last 1 quarters is 15.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Tango Therapeutics, Inc.'s current operating margin is -178.4%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Tango Therapeutics, Inc.'s business trajectory between earnings reports.